Volume 18, Issue 71 (10-2009)                   JGUMS 2009, 18(71): 13-18 | Back to browse issues page

XML Persian Abstract Print


1- Guilan University of Medical Sciences , maghajanzadeh@yahoo.com
2- Guilan University of Medical Sciences
Abstract:   (14941 Views)
Abstract Introduction: Although significant advantages has been made in treatment of esophageal cancer, but this malignant tumor present as locally advanced disease with poor prognosis. Objective: Comparison of effect of Chemoradiation(CRT) with Surgery and Chemoradiation (CRTS) in Esophageal Cancer outcome. Materials and Methods: An analytical-descriptive study was done on 71 patients respectively from 2004 to 2006. Adequate data was achieved positive results of biopsy through the time of last visit or death. The patients divided to two groups, first, chemoradiation (CRT) group and second, postoperative chemoradiation (CRT-S) group. The results were analyzed with Kaplan-Meier and Log-Rank tests. Results: From 71 patients, 42(60%) patients were male and 29(40%) were female. The median age was 66±10 years. 48(68%) patients were treated with CRT treatment and 23(32%) patients had CRT-S treatment. The patients with <65 years old (14 months) had better survival from >65 years old (11 months). Survival in female and male was 13 and 11 months, respectively. There was no significant difference between the overall survival of CRT group (11.5 months) and CRT-S group (13 months) (p>0.05). The median time of survival was 12 months. Conclusion: Despite many reports that shows CRT-S have better outcome than CRT alone, but in our report there was no significant difference between two groups. We conclude that esophageal surgeon must be familiarly with CRT which is a useful protocol for treatment of esophageal carcinoma.
Full-Text [PDF 175 kb]   (1891 Downloads)    
Review Paper: Research | Subject: Special
Received: 2013/11/19 | Accepted: 2013/11/19 | Published: 2013/11/19

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.